Genta Cancer Drug's Timeline Is in Doubt
Genta (GNTA) is still enrolling patients in late-stage studies of its experimental cancer drug Genasense, raising questions about the biotech firm's ability to meet aggressive timelines for the drug's development.
Genta CEO Ray Warrell has long refused to discuss the status of its clinical trial program, citing corporate policy. Instead, he has asked investors and analysts to take a "trust us" attitude -- insisting that the three Phase III Genasense trials are proceeding smoothly, that test results will be ready this summer, and that an approval application for Genasense will be filed with U.S. drug regulators by the end of the year.
An investigation by TheStreet.com has uncovered more than a dozen cancer research centers across the country still enrolling patients in all three Genasense clinical trials, which may be news to investors and Wall Street analysts, who have long assumed that Genta's clinical trials were nearing completion or were already finished.
TheStreet was unable to find a hospital in the U.S. that had completed patient enrollment in a Genta-sponsored trial. Some of these hospitals say they expect to continue signing up patients for Genasense studies through this summer.This prompted Warrell to acknowledge Thursday that patients are still being sought for all three cancer trials. But he deflects suggestions that this is a problem. "There are no headlines here," he says, adding, "Genasense's timelines are not slipping." The fact that trials are still very much a work in progress raises two concerns: First, any conclusions reached about Genasense this summer will be preliminary at best, and subject to change once the trials are completed. Second, the risk increases that Genta can't complete the work necessary to get Genasense to the Food and Drug Administration by year's end as expected.
Genta's stock is depressed
Genta closed Thursday at $12.34 per share. The stock has lost 33% since hitting its 52-week high of $18.49 on March 22, despite news on Monday that it inked a Genasense
The Time CrunchSo, what does all this mean for investors? Delays in the Genasense clinical trials don't necessarily mean the drug isn't working -- this won't be known until all the data are analyzed. But it could weaken the foundation of the bull story on Genta, which reasons that three concurrent clinical trials gives the company much higher odds of success this summer, when data are ready for analysis. After all, most biotech companies only get one shot at hitting the jackpot because they typically run one late-stage trial at a time. But the summer months are fast approaching and Genta is still enrolling patients, and as Warrell confirms, the company will not be able to render a comprehensive verdict on the efficacy of Genasense.
A Battleground StockInvestors hoping for guidance from Wall Street analysts should probably look elsewhere. None of the eight analysts following Genta have raised the patient enrollment issue. Recent comments made by Needham's biotech analyst Mark Monane are representative of the consensus opinion of sell-side analysts. "Genta's flagship pipeline drug, Genasense, is undergoing three Phase III trials, all of which are expected to complete in the Summer 2002 time frame," Monane wrote in an April 30 research note. The Needham analyst has been telling clients that Genasense will be approved and launched in early 2003. He rates Genta a strong buy and his firm has a banking relationship with the company. Genta is probably the biggest battleground stock in biotech right now. Short-sellers control more than 13 million shares, or 16% of its approximately 80 million fully diluted shares, which include outstanding warrants. On the long side, one well-known biotech fund manager, Lyndsay Rosenwald, owns more than 40% of the company through his firm, Paramount Capital. The company is so controversial because Genasense relies on as-yet-unproven cancer-fighting technology called antisense. These kinds of drugs are actually snippets of genetic code that work by infiltrating cells and preventing expression of certain harmful proteins. Or, so the theory goes. Antisense technology has taken investors on a mostly downhill ride for more than 10 years, as waves of drugs failed to live up to the hype. Many investors see Genasense as the antisense drug that will finally break the losing streak, based on earlier clinical studies that have shown some positive results. If Genta can get Genasense approved, it plans to market the drug as a chemotherapy sensitizer, which means it will be used to weaken cancer cells so existing chemo drugs can boost their cancer-killing power. Genta's Warrell has boldly predicted that the drug is a blockbuster -- a billion-dollar seller. Genta's critics, and there are many out there, point to the same early research and say much of it is inconclusive at best. They also criticize Genta executives for being too secretive about its clinical trial program. The final verdict on Genasense won't be known until Genta releases final results from its three Phase III clinical trials and the FDA gets a chance to rule on their efficacy. Just exactly when this will happen, though, now seems to be up for debate.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV